专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09539320B2 Vaccine immunotherapy 有权
公开(公告)号：US09539320B2
公开(公告)日：2017-01-10
申请号：US13320584
申请日：2010-05-17
申请人： John W. Hadden , Kathy Signorelli , James Egan , Paul Naylor
发明人： John W. Hadden , Kathy Signorelli , James Egan , Paul Naylor
IPC分类号： A61K45/00 , A61K39/39 , A61K38/16 , A61K38/17 , A61K38/19 , A61K38/20 , A61K38/21 , A61K39/00 , A61K45/06 , A61K39/395
CPC分类号： A61K39/39 , A61K38/164 , A61K38/177 , A61K38/191 , A61K38/193 , A61K38/2006 , A61K38/2013 , A61K38/204 , A61K38/2053 , A61K38/208 , A61K38/217 , A61K39/0011 , A61K39/39558 , A61K45/06 , A61K2039/55522 , A61K2039/55561 , A61K2039/55588 , A61K2039/6081 , A61K2300/00
摘要： A composition for treating cancer, including synergistic amounts of a primary cell-derived biologic having the cytokines IL-1, IL-2, IL-6, IL-8, TNF-α, and IFN-γ, and a cancer vaccine having at least one antigen. A composition comprising synergistic amounts of the primary cell-derived biologic in combination with at least one adjuvant. A method of treating cancer by administering the composition. A method of reversing immune suppression and gaining immunity to cancer. A method of producing an immune response to an exogenous antigen. A method of enhancing an immune response in a patient by administering the primary cell-derived biologic in combination with at least one adjuvant, and enhancing the immune response of the patient by a synergistic interaction of the primary cell-derived biologic and the adjuvant. A method of increasing function of an immune system.

2. 发明申请

US20120064035A1 VACCINE IMMUNOTHERAPY 有权
标题翻译：疫苗免疫
公开(公告)号：US20120064035A1
公开(公告)日：2012-03-15
申请号：US13320584
申请日：2010-05-17
申请人： John W. Hadden , Kathy Signorelli , James Egan , Paul Naylor
发明人： John W. Hadden , Kathy Signorelli , James Egan , Paul Naylor
IPC分类号： A61K38/21 , A61P37/04 , A61P35/00
CPC分类号： A61K39/39 , A61K38/164 , A61K38/177 , A61K38/191 , A61K38/193 , A61K38/2006 , A61K38/2013 , A61K38/204 , A61K38/2053 , A61K38/208 , A61K38/217 , A61K39/0011 , A61K39/39558 , A61K45/06 , A61K2039/55522 , A61K2039/55561 , A61K2039/55588 , A61K2039/6081 , A61K2300/00
摘要： A composition for treating cancer, including synergistic amounts of a primary cell-derived biologic having the cytokines IL-1, IL-2, IL-6, IL-8, TNF-α, and IFN-γ, and a cancer vaccine having at least one antigen. A composition comprising synergistic amounts of the primary cell-derived biologic in combination with at least one adjuvant. A method of treating cancer by administering the composition. A method of reversing immune suppression and gaining immunity to cancer. A method of producing an immune response to an exogenous antigen. A method of enhancing an immune response in a patient by administering the primary cell-derived biologic in combination with at least one adjuvant, and enhancing the immune response of the patient by a synergistic interaction of the primary cell-derived biologic and the adjuvant. A method of increasing function of an immune system.
摘要翻译：一种用于治疗癌症的组合物，包括具有细胞因子IL-1，IL-2，IL-6，IL-8，TNF-α和IFN-γ的原代细胞衍生生物的协同量，以及具有至少一种抗原。一种组合物，其包含与至少一种佐剂组合的协同量的原代细胞来源的生物制剂。通过施用组合物治疗癌症的方法。逆转免疫抑制和获得癌症免疫力的方法。产生对外源性抗原的免疫应答的方法。一种通过将主要细胞来源的生物与至少一种佐剂组合施用来增强患者的免疫应答的方法，以及通过所述原代细胞衍生的生物学和佐剂的协同相互作用增强患者的免疫应答。增加免疫系统功能的方法。

3. 发明申请

US20050148538A1 Adjuvant formulations for bacterial and virus vaccines and method of making same 审中-公开
标题翻译：细菌和病毒疫苗的辅助配方及其制备方法
公开(公告)号：US20050148538A1
公开(公告)日：2005-07-07
申请号：US10500602
申请日：2002-07-26
申请人： John Hadden , Paul Naylor , Kathy Signorelli
发明人： John Hadden , Paul Naylor , Kathy Signorelli
IPC分类号： A61K39/39 , A61K31/7076 , A61K39/00 , A61K39/02 , A61K39/12 , A61K39/38
CPC分类号： A61K39/39 , A61K2039/55511 , A61K2039/55566 , A61K2039/57
摘要： A pharmaceutical composition including an adjuvant effective amount of a protected inosine monophosphate (IMP) compound. The pharmaceutical composition includes the protected IMP compound alone, or in combination with vaccine agents with or without additional adjuvants. The pharmaceutical composition can be utilized as a vaccine composition or can be included with existing vaccine compositions in order to increase a specific T lymphocyte mediated immune response thereto. Various methods relating to the pharmaceutical composition and N the vaccine are described herein. The vaccines can be employed to prevent or treat infections. Additionally, the pharmaceutical compositions not only increase T-cell responses, but also confer, by pretreatment, non-specific protection against a variety of pathogens. This combination of actions is appropriate for enhancing defense against bioterrorism with organisms like smallpox or anthrax.
摘要翻译：一种药物组合物，其包含佐剂有效量的受保护的一肌糖苷（IMP）化合物。药物组合物包括单独的受保护的IMP化合物，或与具有或不具有另外的佐剂的疫苗剂组合。药物组合物可以用作疫苗组合物，或者可以与现有疫苗组合物一起使用，以便增加对其的特异性T淋巴细胞介导的免疫应答。本文描述了与药物组合物和N疫苗有关的各种方法。疫苗可用于预防或治疗感染。此外，药物组合物不仅增加T细胞应答，而且还通过预处理赋予针对各种病原体的非特异性保护。这种行动的组合适用于加强与天花或炭疽等生物恐怖主义的防御。

4. 发明申请

US20110076249A1 IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS 审中-公开
公开(公告)号：US20110076249A1
公开(公告)日：2011-03-31
申请号：US12960130
申请日：2010-12-03
申请人： John W. Hadden , Paul Naylor
发明人： John W. Hadden , Paul Naylor
IPC分类号： A61K38/20 , A61K31/192 , A61K31/405 , A61K31/66 , A61K38/19 , A61K38/21 , A61P29/00 , A61P35/00 , A61P31/00
CPC分类号： A61K38/193 , A61K31/192 , A61K31/405 , A61K31/675 , A61K38/191 , A61K38/2006 , A61K38/2013 , A61K38/204 , A61K38/2053 , A61K38/208 , A61K38/217 , A61K45/06 , A61K2300/00
摘要： The present invention provides compositions of a natural cytokine mixture (NCM) for treating a cellular immunodeficiency characterized by T lymphocytopenia, one or more dendritic cell functional defects such as those associated with lymph node sinus histiocytosis, and/or one or more monocyte functional defects such as those associated with a negative skin test to NCM. The invention includes methods of treating these cellular immunodeficiencies using the NCM of the invention. The compositions and methods are useful in the treatment of diseases associated with cellular immunodeficiencies such as cancer. Also provided are compositions and methods for reversing tumor-induced immune suppression comprising a chemical inhibitor and a non-steroidal anti-inflammatory drug (NSAID). The invention also provides a diagnostic skin test comprising NCM for predicting treatment outcome in cancer patients.

5. 发明申请

US20110110884A1 IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS 审中-公开
标题翻译：免疫抑制患者免疫
公开(公告)号：US20110110884A1
公开(公告)日：2011-05-12
申请号：US12282972
申请日：2007-03-09
申请人： John W. Hadden , Paul Naylor
发明人： John W. Hadden , Paul Naylor
IPC分类号： A61K38/20 , A61K38/19 , A61K31/405 , A61K31/192 , A61K31/66 , A61K38/21 , A61P35/00 , A61P31/00 , A61P29/00
CPC分类号： A61K38/193 , A61K31/192 , A61K31/405 , A61K31/675 , A61K38/191 , A61K38/2006 , A61K38/2013 , A61K38/204 , A61K38/2053 , A61K38/208 , A61K38/217 , A61K45/06 , A61K2300/00
摘要： The present invention provides compositions of a natural cytokine mixture (NCM) for treating a cellular immunodeficiency characterized by T lymphocytopenia, one or more dendritic cell functional defects such as those associated with lymph node sinus histiocytosis, and/or one or more monocyte functional defects such as those associated with a negative skin test to NCM. The invention includes methods of treating these cellular immunodeficiencies using the NCM of the invention. The compositions and methods are useful in the treatment of diseases associated with cellular immunodeficiencies such as cancer. Also provided are compositions and methods for reversing tumor-induced immune suppression comprising a chemical inhibitor and a non-steroidal anti-inflammatory drug (NSAID). The invention also provides a diagnostic skin test comprising NCM for predicting treatment outcome in cancer patients.
摘要翻译：本发明提供了一种天然细胞因子混合物（NCM）的组合物，其用于治疗以T淋巴细胞减少为特征的细胞免疫缺陷，一种或多种树突细胞功能缺陷，例如与淋巴结窦组织细胞增多症有关的功能缺陷，和/或一种或多种单核细胞功能缺陷如与NCM的阴性皮肤试验相关的那些。本发明包括使用本发明的NCM治疗这些细胞免疫缺陷的方法。组合物和方法可用于治疗与细胞免疫缺陷如癌症相关的疾病。还提供了用于逆转肿瘤诱导的免疫抑制的组合物和方法，包括化学抑制剂和非甾体抗炎药（NSAID）。本发明还提供了一种诊断性皮肤试验，其包括用于预测癌症患者的治疗结果的NCM。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式